Pharnext

February 7, 2019February 7, 2019

FDA Grants Fast Track Designation to Pharnext’s PXT3003 for CMT1A

News

Pharnext‘s PXT3003 was granted fast track designation for Charcot-Marie-Tooth disease type 1A (CMT1A) by the U.S. Food and Drug Administration, the company announced. “We are pleased to receive Fast Track designation for ... Read more

January 24, 2019January 24, 2019

Short-term PXT3003 Treatment Delays Disease Onset in Rat Model of CMT1A, Study Shows

News

Two weeks of treatment with Pharnext’s PXT3003 delayed disease onset, corrected motor deficits, and improved dysregulated molecular pathways in a young rat model of Charcot-Marie-Tooth disease type 1A (CMT1A), a preclinical ... Read more

October 19, 2018October 19, 2018

International CMT&Me Observational Study to Explore the Impact of CMT Using an App

News

A newly launched international observational study is going to explore the overall impact of Charcot-Marie-Tooth disease (CMT) using a tailored app called CMT&Me. Designed by Vitaccess in collaboration with ... Read more

October 17, 2018October 17, 2018

PXT3003 Eases Disability, Found Safe in CMT1A Patients, Phase 3 Trial Shows

News

Investigational compound PXT3003 consistently eased disability in patients with mild to moderate Charcot-Marie-Tooth disease type 1A (CMT1A), according to top-line Phase 3 results from Pharnext, which also found that the ... Read more

October 15, 2018

Hereditary Neuropathy Foundation Hosts FDA Patient-Focused Drug Development Meeting

News

Along with Chris Comish, President and CEO of Charcot-Marie-Tooth’s parent company BioNews Services, I recently had the opportunity to attend the FDA Patient-Focused Drug Development (PFDD) Meeting for Charcot-Marie-Tooth ... Read more

June 27, 2018June 27, 2018

Pharnext Shares Top-Line Results from Pivotal Phase 3 Studies of PXT3003; More to Come

News

Pharnext recently provided an update from its ongoing Phase 3 clinical trials evaluating PXT3003 for treating Charcot-Marie-Tooth disease type 1A (CMT1A) in adults, and also announced that some top-line results ... Read more

June 15, 2018June 15, 2018

Pharnext’s PXT3003 Granted Priority Review in China for Charcot-Marie-Tooth Type 1A

News

The French biopharmaceutical company Pharnext recently announced that its candidate for the treatment of Charcot-Marie-Tooth disease type 1A (CMT1A) was granted priority review by the China Food and Drug Administration (CFDA). ... Read more

April 13, 2018April 13, 2018

Pharnext, Developer of CMT1A Treatment Candidate PXT3003, Raises 16 Million Euros

News

Pharnext SA — the French biopharmaceutical company developing PXT3003 as a therapeutic candidate to treat Charcot-Marie-Tooth disease type 1A (CMT1A) — announced that it has successfully raised 16 million euros, ... Read more

December 1, 2017December 6, 2017

Phase 3 Trial of Potential Treatment for CMT Type 1A, PXT3003, Cleared to Continue by Independent Board

News

Intermediate analyses were positive for a Phase 3 clinical trial evaluating Pharnext’s PXT3003 as a possible treatment for people with Charcot-Marie-Tooth disease type 1A (CMT1A). Results of the two planned analyses ... Read more

September 8, 2017

Safety Board OKs Continuation of Phase 3 Trial of PXT3003 as a Charcot-Marie-Tooth Treatment

News

A safety review board has recommended that regulators allow Pharnext to continue conducting its Phase 3 clinical trial of PXT3003 as a treatment for the neurodegenerative disease Charcot-Marie-Tooth type 1A (CMT1A). It was ... Read more

Pin It on Pinterest